# RGL-270 + ICI in Advanced NSCLC

> **NCT07652125** · NA · RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 40 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **BIOLOGICAL:** RGL-270 in Combination with PD-1/PD-L1 Inhibitors
- **OTHER:** Physician's Choice SOC

## Key facts

- **NCT ID:** NCT07652125
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-25
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652125, "RGL-270 + ICI in Advanced NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*